STOCK TITAN

Alkermes plc. (ALKS) SEC Filings, Oct 2025-Feb 2026

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of $31.64 per share as the options approached their 02/28/2026 expiration.

That same day, he sold 29,087 ordinary shares at a weighted average price of $34.3382 per share and 32,113 ordinary shares at a weighted average price of $34.7796 per share in multiple transactions. After these trades, Cooke directly owned 103,744 ordinary shares of Alkermes plc.

The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on 02/27/2025, and that the options were fully vested in accordance with their terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
insider
-
Rhea-AI Summary

A holder of Alkermes plc ordinary shares has filed a Rule 144 notice to sell 61,200 shares. The shares are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026 and an aggregate market value of $2,115,674.45.

The 61,200 ordinary shares were acquired on 02/02/2026 through the exercise of employee stock options in a broker-assisted cashless exercise. The filing notes that 165,117,509 ordinary shares were outstanding, providing context for the size of the planned sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
other
-
Form 144
Rhea-AI Summary

Alkermes plc insider Craig Hopkinson has filed a notice to sell ordinary shares under Rule 144. The filing covers 9,000 ordinary shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $305,384.28 and 165,117,509 shares outstanding.

The shares come from a broker-assisted cashless exercise of 5,000 employee stock options on 02/02/2026 and vesting of restricted stock unit awards totaling 4,000 shares during February 2025. The form also lists several prior ordinary share sales by Hopkinson over the past three months with disclosed gross proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
other
Rhea-AI Summary

Alkermes plc filed a current report describing a new corporate presentation it will use at the J.P. Morgan Healthcare Conference. The presentation, furnished as Exhibit 99.1, includes the company’s estimated total revenues for the year ended December 31, 2025. These revenue figures are described as preliminary, unaudited and subject to change once Alkermes completes its review of its 2025 financial statements.

The company notes that the information in Items 2.02 and 7.01, and in Exhibit 99.1, is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings unless specifically referenced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
current report
-
Rhea-AI Summary

Alkermes plc insider Craig Hopkinson has filed a Form 144 notice to sell ordinary shares. The filing covers 5,000 ordinary shares to be sold through Merrill Lynch on or about 01/08/2026 on NASDAQ, with an aggregate market value of $150,004.95. The filing notes 165,117,509 ordinary shares outstanding.

The 5,000 shares were acquired on 01/08/2025 through the exercise of employee stock options in a broker-assisted cashless exercise. The notice also lists prior sales over the past three months, including 9,000 ordinary shares sold on 10/15/2025 for gross proceeds of $283,776.70 and 9,000 shares sold on 11/03/2025 for $273,441.50, along with additional smaller transactions in December 2025 and early January 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.20%
Tags
other
-
Rhea-AI Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an options exercise and share sale. On 01/08/2026 he exercised an employee stock option for 5,000 ordinary shares at an exercise price of $19.34 per share and then sold 5,000 ordinary shares at a weighted average price of $30.001 per share, with individual sale prices ranging from $30.00 to $30.01.

Both the option exercise and the sale were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, and the options exercised were fully vested in accordance with their terms. After these transactions, he directly owned 61,740 ordinary shares and 31,356 employee stock options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.20%
Tags
insider
Rhea-AI Summary

Alkermes plc amended its agreement to acquire Avadel Pharmaceuticals, raising the cash offer from $18.50 to $21.00 per Avadel share, while keeping the potential additional $1.50 per share contingent value right unchanged. Alkermes also entered into an amended and restated senior secured bridge term loan facility of up to $1,512,562,923.28 to help fund the cash consideration and related fees and expenses for the Acquisition. The bridge loans, if drawn, will mature 364 days after funding and bear interest at either a Term SOFR-based rate plus 3.00% or an Alternate Base Rate plus 2.00%, with margin step-ups over time. Alkermes continues to expect completion of the Acquisition in the first quarter of 2026, subject to satisfaction or waiver of the stated conditions, and J.P. Morgan Securities LLC has confirmed sufficient resources are available to pay the cash consideration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
current report
-
Rhea-AI Summary

Alkermes plc reported positive topline results from Vibrance‑2, a randomized, double‑blind phase 2 study of alixorexton (formerly ALKS 2680) versus placebo in patients with narcolepsy type 2.

The company hosted an investor webcast and conference call to present the topline data, and furnished a press release as Exhibit 99.1 and an investor presentation as Exhibit 99.2. Information in Item 7.01 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
current report
-
Rhea-AI Summary

Alkermes plc (ALKS) reported an insider transaction by its EVP R&D and Chief Medical Officer, Craig C. Hopkinson. On 11/03/2025, he exercised 5,000 employee stock options at $19.34 and, on the same date, sold 9,000 ordinary shares at a weighted average price of $30.3824.

Both the option exercise and the sale were made under a Rule 10b5-1 trading plan adopted on 3/14/2025. The filing notes the sale occurred in multiple transactions at prices ranging from $30.34 to $30.56. Following these transactions, he directly beneficially owned 69,740 ordinary shares. He also reported 40,104 derivative securities (stock options) remaining. The options exercised were fully vested and carry an expiration date of 02/22/2031.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
insider
Rhea-AI Summary

Alkermes plc (ALKS) reported Q3 2025 results with total revenue of $394.2 million, up modestly from $378.1 million a year ago. Product sales rose to $317.4 million, led by VIVITROL $121.1 million, ARISTADA/ARISTADA INITIO $98.1 million, and LYBALVI $98.2 million. Manufacturing and royalty revenue declined to $76.8 million, reflecting the August 2024 expiry of U.S. royalties on INVEGA SUSTENNA.

Operating income was $89.1 million versus $104.8 million, and net income was $82.8 million (diluted EPS $0.49) versus $92.4 million ($0.55). Year-to-date, revenue was $1.09 billion versus $1.13 billion, with net income of $192.3 million versus $220.6 million.

Cash and cash equivalents increased to $616.4 million from $291.1 million at year-end, supported by $350.7 million in operating cash flow for the first nine months. Short-term investments were $494.7 million. The company reduced Medicaid rebate reserves due to lower-than-expected actual rebates, including approximately $25.3 million for VIVITROL and $12.1 million for ARISTADA/ARISTADA INITIO. Shares outstanding were 165.1 million as of October 24, 2025. No repurchases occurred in 2025; $200.0 million remains authorized.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
quarterly report

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.